SERCA-LVAD
Trial Details
- Trial statusAnalysis
- Study email contactsercalvad-trial@imperial.ac.uk
- Chief InvestigatorDr Alexander Lyon
- Project managerDr Thiagarajah Sasikaran
- SponsorImperial College London
- Phase2
- View clinicaltrials.gov website
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device
Design and Objective
This study is being performed to understand if gene transfer to increase SERCA2a protein may help patients with heart failure. Researchers have found that failing hearts have lost a protein called SERCA2a, which controls the strength of the heart muscle. Increasing the levels of this protein improves the contraction and relaxation of the heart. The purpose of this research study is to understand more about SERCA gene delivery.
Key inclusion criteria
1. Patients that have had a left ventricular assist device (LVAD) implanted for chronic heart failure, where chronic heart failure is defined as at least 6 months 2. Patients are clinically stable in the opinion of the clinical team looking after the patient 3. Written informed consent